EBEvgeniy A. Burtsev

Evgeniy A. Burtsev

*This is an algorithmically generated author record based on publicly available information.

Evgeniy A. Burtsev has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A multicenter study of allogeneic HSCT in Nijmegen breakage syndrome with conditioning regimen based on reduced doses of treosulfan

    by A. Laberko, E. Skorobogatova, O. Slesarchuk, I. Vlasova, L. Vakhonina, L. Shelikhova, Y. Skvortsova, E. Lyudovskikh, E. Burtsev, T. Bykova, et al.

  • EFFICACY OF VEMURAFENIB COMBINED WITH CYTARABINE AND 2-CHLORO-2′-DEOXYADENOSINE AS FIRST-LINE THERAPY IN CHILDREN WITH MULTISYSTEM LANGERHANS CELL HISTIOCYTOSIS

    by E.A. Burtsev, D.A. Evseev, D.S. Osipova, G.Z. Seregin, D.D. Baydildina, I.I. Kalinina, E.V. Kumirova, A.A. Maschan, M.A. Maschan

    Langerhans cell histiocytosis (LCH) is the most common histiocytic disorder of childhood, driven by pathological activation of the MAPK signaling pathway. The multisystem form with riskorgan involvement (RO+) carries the worst prognosis. BRAF inhibitors show high initial efficacy, but monotherapy is associated with a high reactivation rate after discontinuation, underscoring the need to optimize first-line therapy. Objective: To evaluate the efficacy and tolerability of a combined protocol of vemurafenib with reduced-dose cytarabine (ARA-C) and 2-chloro-2′-deoxyadenosine (2-CdA) as first-line therapy in children with BRAF-positive multisystem LCH. Materials and Methods: A retrospective two-center observational study. Children with BRAF+ multisystem LCH (RO+ and RO–) treated with the protocol as first-line therapy in 2022–2025 were included. The protocol comprised 4 courses of vemurafenib (20 mg/kg/day) alternating with blocks of ARA-C (200 mg/m2/day) and 2-CdA (6 mg/m2/day) at reduced doses; total duration 196 days. Disease activity was assessed with the Disease Activity Score (DAS); complete response (non-active disease, NAD) was defined as 0 points. Event-free survival (EFS) was estimated by the Kaplan–Meier method; the Wilcoxon signed-rank test was used to compare DAS before and after treatment. Results: Twenty patients were enrolled (RO+, n=16; RO–, n=4). In the RO+ group, median age was 9 (1–22) months and median DAS 13 (5–16). NAD was achieved in all 20 (100%) patients, most by the first assessment point. Five-year EFS in the RO+ group was 75%. Reactivation occurred in 3/16 RO+ and 1/4 RO– patients; re-initiation of targeted therapy was effective in all cases. No grade III–IV toxicity (CTCAE v5.0) or disease progression was observed. A decline in BRAF-V600E allelic burden was seen in all 8 evaluated patients. Conclusion: First-line vemurafenib combined with reduced-dose ARA-C/2-CdA achieves NAD in all patients with low organ toxicity and may be considered an alternative to existing first-line regimens in children with multisystem LCH, both RO+ and RO–.

  • Allogeneic transplantation of hematopoietic stem cells in congenital pyruvate kinase deficiency. Case report

    by B. M. Kurmanov, E. A. Burtsev, I. O. Vlasova, E. A. Zhuravel, E. V. Kumirova, S. I. Valieva

    Hemolytic anemia due to pyruvate kinase deficiency is a rare congenital disease caused by a defect in the glycolytic pathway. This anemia is the most common among all enzymopathies. There are various treatment methods for this disease. This article presents a clinical case of a successful allogeneic hematopoietic stem cell transplantation in a patient with pyruvate kinase deficiency.

  • Belumosudil in the treatment of steroid-refractory chronic graft-versus-host disease in children: the combined experience of nine centers of the Russian Federation

    by Т. A. Bykova, K. I. Kirgizov, I. O. Kostareva, E. A. Burtsev, N. S. Klimov, Yu. V. Skvortsova, O. O. Molostova, M. M. Antoshin, L. G. Fechina, L. V. Vakhonina, et al.

    Introduction. Chronic graft-versus-host disease (cGVHD) remains a serious complication of allogeneic hematopoietic stem cell transplantation in children. In steroid-refractory cases, the prognosis is still unfavorable, and data on the use of the selective ROCK2 inhibitor belumosudil in the pediatric population, particularly in children under 12 years of age, are limited. Materials and methods . A retrospective multicenter analysis was conducted on 43 patients aged ≤ 18 years with steroid-refractory or steroiddependent cGVHD (2014 NIH criteria) who received belumosudil in 9 transplant centers across the Russian Federation between 2023 and 2025. The dose of the drug was determined by the patient's body weight, ranging from 50 to 200 mg/day. The evaluation included the rate and speed of achieving an overall response (complete and partial responses), organ-specific efficacy, safety profile, as well as the frequency of dose reduction, temporary interruptions, and treatment discontinuation. Results. The median age of patients at the start of therapy was 12 years (range: 2–18 years). The median number of prior lines of therapy was 3. An overall response was achieved in 65 % of patients (28/43): a complete response in 5 % (2/43) and a partial response in 60 % (26/43). The highest rates of organ-specific responses were observed in lung involvement (79.5 %), gastrointestinal tract (64 %), oral mucosa, and eyes (65.5 % and 68.5 %, respectively). The median time to response was 35 days. Adverse events of any grade were reported in 70 % of patients, with serious events occurring in 37 %. The most frequent were infectious complications (56 %), hematological toxicity (37 %), and hepatotoxicity (21 %). Dose reduction was required in 35 % of patients, a temporary interruption in 21 %, and treatment discontinuation in 19 %. Conclusion . Belumosudil demonstrated clinically significant efficacy and a manageable safety profile in pediatric patients with severe steroid-refractory cGVHD, including children under 12 years of age. The data obtained add to the limited global publications on the use of belumosudil in pediatrics and support the feasibility of conducting prospective studies.

  • Open Access

    Treatment of lymphoblastic lymphomas in children in Russia: preliminary results of a multicenter retrospective study

    by E. V. Volchkov, T. Yu. Pavlova, G. I. Shestopalov, L. S. Zubarovskaya, A. V. Protsvetkina, E. A. Burtsev, D. S. Abramov, G. R. Kazaryan, V. V. Martynenko, K. A. Tsytsylina, et al.

    Background. Lymphoblastic lymphomas (LBL) are an aggressive variant of non-Hodgkin’s lymphomas (NHL), which ranks second in frequency among non-Hodgkin’s lymphomas in children. According to international data, the effectiveness of LBL therapy in children reaches 85 %. In Russia, information on the treatment results for this disease is extremely limited. Aim. To present preliminary data on the results of LBL therapy in children in Russia. Materials and methods. The study included 392 pediatric LBL patients, treated in 57 specialized hospitals of the Russian Federation from 1999 to 2024. Results. The overall and event-free survival rates were 83 % (95 % confidence interval 78–88) and 70 % (95 % confidence interval 64–78), respectively. In addition, the analysis revealed a high frequency of thrombotic complications (29 % of all patients), especially in cases of T-cell LBL. No significant differences in disease outcomes were found between tumor immunophenotypes, the type of asparaginase, and the stage of the disease. A separate analysis of the results of LBL therapy according to the ALL IC-BFM 2002 / 2009 protocols (146 patients) with stricter criteria for the response to induction therapy (tumor reduction of more than 70 %) and early chemotherapy intensification with high-dose blocks at the N. N. Blokhin National Medical Research Center of Oncology showed the event-free and overall survival of about 90 %. The Cox regression model of the dependence of therapy outcomes on residual tumor volume at the end of induction in the main cohort of patients did not reveal an association between residual tumor volume and overall survival (p = 0.2), but there was a statistical association with event-free survival (p = 0.006). Discussion. This paper presents preliminary data from the first multicenter study of LBL therapy in pediatric patients in the Russian Federation. According to our data, LBL survival rates in the Russia should be improved. An important problem in the treatment of LBL in children is therapy complications, especially the high incidence of thrombosis. In this regard, anticoagulant prophylaxis is recommended for patients with LBL, especially with the T-cell phenotype and the presence of risk factors. Further studies are also needed to identify high-risk patients for the development of new personalized therapy approaches. Conclusion. The paper presents preliminary results from the first multicenter clinical study of LBL therapy in children in Russia, indicating the necessity of treatment approaches improvement for increase a treatment effectiveness.

  • Open Access

    Secondary Hemophagocytic Lymphohistiocytosis in a Child with Myeloid Sarcoma: A Literature Review and Case Report

    by G. O. Bronin, A. A. Bystrova, K. L. Kondratchik, E. A. Burtsev, M. V. Natrusova, Galimat Abdulkhalikovna Radjabova, E. V. Kumirova, A. M. Kovrigina, T. T. Valiev

    Вторичный гемофагоцитарный лимфогистиоцитоз (ГЛГ) является редким и опасным осложнением злокачественных новообразований у детей. Сложность подобных клинических ситуаций заключается в том, что вторичный ГЛГ затрудняет диагностику и своевременное начало лечения опухолевого заболевания. В настоящей публикации представлено собственное клиническое наблюдение вторичного ГЛГ у ребенка в возрасте 2 лет и 5 мес. При детальном обследовании больной диагностирована миелоидная саркома с поражением костей черепа и лицевого скелета с формированием множественных мягкотканных объемных образований. Предпринятые попытки купирования симптомов вторичного ГЛГ и программное лечение миелоидной саркомы не увенчались успехом. Учитывая высокую летальность и недостаточную эффективность существующих подходов к лечению вторичных ГЛГ, представляется крайне важным изучение и внедрение новых терапевтических стратегий с включением таргетных препаратов.

  • Open Access

    Fecal microbiota transplantation for the treatment of intestinal diseases after allogeneic hematopoietic stem cell transplantation in children

    by G. Z. Seregin, Yu. A. Bespyatykh, A. V. Gospodarik, M. Yu. Kirillov, L. V. Ogneva, S. V. Zhilina, E. A. Burtsev, A. E. Burya, I. O. Vlasova, M. R. Zhuravel, et al.

    Fecal microbiota transplantation (FMT) is a promising therapy for a variety of diseases involving the gastrointestinal (GI) tract. The purpose of our study is to evaluate the effectiveness of FMT for the treatment of different GI complications after allogenic hematopoietic stem cell transplantation (steroid-refractory and steroid-dependent graft versus host disease (SR/ SD GVHD) and infectious enterocolitis) in children from 1.5 to 18 years old. The study was approved by the Local Ethics Committee of the Morozov Children's Clinical Hospital of the Department of Health of Moscow (No. 176 dated 24.05.2022). The patients' parents gave their informed consent to the participation of their children in the study and the publication of the study results. SR/SD GVHD group included 14 patients and GI infections group – 11 patients. In total, 38 FMTs were performed. Eleven children underwent repeated FMTs due to the lack of effect after the first FMT. The resolution of diarrhea followed by the withdrawal of corticosteroids was recorded in 11 out of 14 patients with SR/SD GVHD. Ten out of 11 patients with GI infections also achieved relief of diarrhea. The clinical effect correlated with changes in the microbiome structure: for both groups of patients, the median proportion of normal microbiota before FMT was 6%, after FMT – 92% (p = 0.043). The median number of different taxa for both groups of patients before and after FMT were 3 and 10 taxa, respectively (p = 0.0016).


  • Open Access

    The use of BRAF-inhibitors as monotherapy and in combination with cytosine arabinoside and 2-chloro-2’deoxyadenosine in pediatric patients with different forms of Langerhans cell histiocytosis

    by E. A. Burtsev, D. A. Evseev, I. R. Gaziev, L. L. Lebedeva, D. A. Skobeev, D. S. Osipova, G. O. Bronin, M. A. Maschan

    Background. Langerhans cell histiocytosis (LCH) is a rare disease that occurs due to abnormal proliferation and expansion of myeloid precursors. The occurrence of mutations in genes that encode key kinases of MAPK-signaling pathway leads to its pathological activation and has been shown the cause of disease. Mutations in BRAF and MAP2K1 genes are the most frequent among LCH patients. The effectiveness of BRAF-inhibitors in LCH patients has been shown in numerous studies.The purpose of the study – analyze the experience of BRAF-inhibitor vemurafenib administration as monotherapy and in combination with cytosine arabinoside (ARA-C) and 2-chloro-2'-deoxyadenosine (2-CdA) in pediatric patients with different forms of LCH.Materials and methods. Fifteen patients with various forms of LCH were enrolled in the study. BRAF mutations were detected in 14 patients, mutation in the MAP2K1 gene was detected in one case. Patients with “risk organ” (RO) involvement were included in the first group (n = 9). These patients received combined therapy with vemurafenib and ARA-C/2-CdA. Patients without RO involvement, included in group 2 (n = 6), received vemurafenib as monotherapy. The assessment of the response to the therapy in group 1 was carried out in accordance with the DAS scale, in group 2 in accordance with the RECIST v1.1. The toxicity assessment in both groups was carried out in accordance with the CTCAE v5.0.Results. All patients in group 1 achieved non-active disease status with a median of 35 (28–61) days. In group 2 partial response to vemurafenib was achieved in 5 cases. Relapse after targeted therapy termination was diagnosed in two patients. Photodermatitis was the most common side effect of targeted therapy.Conclusions. The use of vemurafenib was effective in both groups. There were no cases of grade III–IV toxicity according to CTCAE v5.0 associated with vemurafenib administration in this study. The combination of vemurafenib and ARA-C/2-CdA showed high efficacy and good tolerability in group 1. Two cases of disease relapse after targeted therapy cessation in group 2 show that the monotherapy approach does not always allow to achieve long-term remission in LCH patients.

  • Open Access

    The results of a study on the effectiveness 37 and safety of treatment with vemurafenib and cytarabine/2-chloro-2′-deoxyadenosine combination in patients with Langerhans cell histiocytosis with BRAFV600E mutation

    by E. I. Lyudovskikh, D. A. Yevseyev, D. S. Osipova, E. V. Raykina, I. I. Kalinina, Д. Д. Байдильдина, A. M. Popov, E. A. Burtsev, G. O. Bronin, O. S. Fink, et al.

    Here, we report on a new treatment protocol for patients with BRAF-positive Langerhans cell histiocytosis (LCH). To achieve remission in the affected patients, we used vemurafenib (a targeted drug) in combination with cytarabine (Ara-C) and cladribine (2-CdA). The study included 27 patients: 18 children with multisystem LCH with risk organ involvement (RO+) and 9 – with multisystem LCH without risk organ involvement (RO–). The treatment started with a 28-day cycle of vemurafenib, with subsequent discontinuation. On Day 29, Аra-C + 2-СdA chemotherapy cycle № 1 was initiated. Vemurafenib treatment was again started on Day +1 after the Ara-C + 2-CdA cycle. The interval between the cycles was 28 days. Similarly, the next two Аra-C + 2-СdA chemotherapy cycles (№ 2 and № 3) were carried out. Then therapy with vemurafenib was stopped and 3 cycles of 2-CdA were administered. All the patients responded to the treatment quickly: on Day 28, disease activity score decreased from 15 to 2 in the RO+ group and from 4 to 0 in the RO– group. The two-year relapse-free survival in the RO+ group was 82 % (95 % confidence interval 66–100), and 89 % (95 % confidence interval 71–100) in the RO– patients. The overall survival in both groups was 100 %. Our study demonstrates the safety and effectiveness of the treatment with vemurafenib and intermediate-dose 2-CdA and Ara-C in children with multisystem RO+ and refractory LCH. This prospective non-randomized multicenter study was approved by the Independent Ethics Committee (Minutes No. 3e/1-18) and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. It is registered at clinicaltrials.gov under the number NCT03585686. The first patient was enrolled on 22 June 2018, the data collection was stopped on 30 April 2023.

  • Open Access

    Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E–positive LCH

    by Dmitry Evseev, Daria Osipova, Irina Kalinina, Elena Raykina, Anna Ignatova, Evelina Lyudovskikh, Dina Baidildina, Alexander Popov, Vladimir Zhogov, Alexandra Semchenkova, et al.

    Langerhans cell histiocytosis (LCH) is a disorder with a variety of clinical signs. The most severe forms affect risk organs (RO). The established role of the BRAF V600E mutation in LCH led to a targeted approach. However, targeted therapy cannot cure the disease, and cessation leads to quick relapses. Here, we combined cytosine-arabinoside (Ara-C) and 2'-chlorodeoxyadenosine (2-CdA) with targeted therapy to achieve stable remission. Nineteen children were enrolled in the study: 13 were RO-positive (RO+) and 6 RO-negative (RO–). Five patients received the therapy upfront, whereas the other 14 received it as a second or third line. The protocol starts with 28 days of vemurafenib (20 mg/kg), which is followed by 3 courses of Ara-C and 2-CdA (100 mg/m2 every 12 h, 6 mg/m2 per day, days 1-5) with concomitant vemurafenib therapy. After that, vemurafenib therapy was stopped, and 3 courses of mono 2-CdA followed. All patients rapidly responded to vemurafenib: the median disease activity score decreased from 13 to 2 points in the RO+ group and from 4.5 to 0 points in the RO– group on day 28. All patients except 1 received complete protocol treatment, and 15 of them did not have disease progression. The 2-year reactivation/progression-free survival (RFS) for RO+ was 76.9% with a median follow-up of 21 months and 83.3% with a median follow-up of 29 months for RO–. Overall survival is 100%. Importantly, 1 patient experienced secondary myelodysplastic syndrome after 14 months from vemurafenib cessation. Our study demonstrates that combined vemurafenib plus 2-CdA and Ara-C is effective in a cohort of children with LCH, and the toxicity is manageable. This trial is registered at www.clinicaltrials.gov as NCT03585686.